Literature DB >> 9371368

Penetration of teicoplanin into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery.

U K Frank1, E Schmidt-Eisenlohr, D Mlangeni, M Schindler, A Hoh, F Beyersdorf, F D Daschner.   

Abstract

Penetration of teicoplanin into serum, heart valves, and subcutaneous and muscle tissues was determined in 22 patients undergoing open-heart surgery. Each patient received 12 mg of teicoplanin per kg of body weight as a 30-min intravenous infusion preoperatively. Within 10 h, serum concentrations of teicoplanin declined from 43.1 to 2.8 microg/ml. Teicoplanin concentrations in subcutaneous tissues reached their peak of 9.2 microg/g after 2 to 3 h and decreased slowly to 2.3 microg/g after 9 to 10 h. Concentrations in muscle decreased from 8.7 microg/g to nondetectable levels. Teicoplanin concentrations in cardiac valvular tissue reached their peak of 6.1 microg/g and decreased thereafter to 1.7 microg/g. Teicoplanin concentrations in heart valves were high enough to inhibit methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci, which are known to cause postoperative wound infections and infective endocarditis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371368      PMCID: PMC164163     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Stomaching: a new concept in bacteriological sample preparation.

Authors:  A N Sharpe; A K Jackson
Journal:  Appl Microbiol       Date:  1972-08

2.  Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci.

Authors:  F W Goldstein; A Coutrot; A Sieffer; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

4.  Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues.

Authors:  C Martin; P Bourget; M Alaya; A Sertin; C Atlani; K Ennabli; R Said
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.

Authors:  E A Gorzynski; D Amsterdam; T R Beam; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

6.  Penetration of ceftazidime into heart valves and subcutaneous and muscle tissue of patients undergoing open-heart surgery.

Authors:  U Frank; I Kappstein; E Schmidt-Eisenlohr; V Schlosser; G Spillner; M Schindler; F D Daschner
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

7.  Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers.

Authors:  J A Smithers; H K Kulmala; G A Thompson; K K Antony; E W Lewis; S J Ruberg; M T Kenny; J K Dulworth; M A Brackman
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 8.  Teicoplanin.

Authors:  K W Shea; B A Cunha
Journal:  Med Clin North Am       Date:  1995-07       Impact factor: 5.456

9.  Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery.

Authors:  F D Daschner; U Frank; A Kümmel; E Schmidt-Eisenlohr; V Schlosser; H Spillner; B Schuster; M Schindler
Journal:  J Antimicrob Chemother       Date:  1987-03       Impact factor: 5.790

10.  Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.

Authors:  E M Bailey; M J Rybak; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

View more
  1 in total

Review 1.  Clinical pharmacokinetics of teicoplanin.

Authors:  A P Wilson
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.